VICTOR: Vericiguat lowers the risk of cardiovascular and all-cause death in patients with heart failure

ESC 2025

Heart Failure

VICTORIA and VICTOR: Vericiguat reduces the risk of both cardiovascular death and HF hospitalizations, as well as all-cause mortality in a broad population of patients with heart failure

Heart Failure

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Clin Res Cardiol

Ojeda-Fernández L, Torrigiani G, Molteni M, Fortino I, Cimminiello C, Baviera M

doi: 10.1007/s00392-025-02674-9

Heart Failure

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure

J Am Heart Assoc

Wettersten N, Duff S, Horiuchi Y, van Veldhuisen DJ, Estrella MM, Shlipak MG, Maisel A, Murray PT, Ix JH

doi: 10.1161/JAHA.125.042880

Heart Failure

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Eur J Heart Fail

Leong DP, Joseph PG, Dokainish H, Störk S, McMurray JVV, Mielniczuk LM, Sharma SK, Orlandini A, Karaye KM, Bayes-Genis A, McCready T, Grinvalds A, Balasubramanian K, Branch KR, Kragholm K, Yusuf S, on behalf of the G‐CHF Investigators

doi: 10.1002/ejhf.3550

Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Eur Heart J

Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F

doi: 10.1093/eurheartj/ehaf655

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score

J Am Heart Assoc

Abassi NK, Nouhravesh N, Elmegaard M, Austreim M, Zahir D, Garred CH, Butt JH, Andersen CF, Strange JE, Sindet-Pedersen C, Christensen DM, Fosbøl E, Andersson C, Køber L, Schou M

doi: 10.1161/JAHA.124.037973

Heart Failure

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Circulation

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators

doi: 10.1161/CIRCULATIONAHA.125.076575

Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Eur J Heart Fail

Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F, VICTOR Study Group

doi: 10.1002/ejhf.70033

Related content

VICTORIA and VICTOR: Vericiguat reduces the risk of both cardiovascular death and HF hospitalizations, as well as all-cause mortality in a broad population of patients with heart failure

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial